If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Product Launch » Market Entry: Metabolic and Cardiovascular Diseases
Download FREE Excerpt
14 Info Graphics
14 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
While many factors affect a pharmaceutical new product launch, it's recognized that payers have become a critical factor in how a metabolic product fares in the marketplace. In response, organizations have incorporated a number of payer-related activities into their pre-launch and launch plans. In particular, launch leaders have learned to focus their efforts on educating payers about a new metabolic product and working with private and public payers to gain access for new products at or as soon as possible following launch.
Best Practices, LLC conducted this research study to discover successful strategies and tactics for educating payers on new therapies and winning managed markets access for new metabolic products. Launch leaders and managed markets executives can use this research to compare their approach to these payer-related launch interactions with the approaches used by leading organizations. This study contains two segments: a metabolic/diabetes segment and a total benchmark class segment.
The research employed a data gathering approach that gleaned quantitative data from nine metabolic leaders, although their participation varied across the question set. In all, there was participation from 44 executives and managers from 38 leading companies in pharmaceutical, biotechnology and medical device industries.